Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levothyroxine Sodium
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Mark Cuban Cost Plus Drug Company
Deal Size : Undisclosed
Deal Type : Agreement
IBSA Pharma and Mark Cuban Cost Plus Drug Company Team Up to Make Tirosint More Affordable
Details : Tirosint capsules is the leading branded gel capsule formulation of levothyroxine sodium in the US. It is formulated without excipients that can cause tolerability and drug absorption problems commonly observed with traditional levothyroxine tablet thera...
Product Name : Tirosint
Product Type : Hormone
Upfront Cash : Undisclosed
July 03, 2023
Lead Product(s) : Levothyroxine Sodium
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Mark Cuban Cost Plus Drug Company
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Levothyroxine Sodium
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Study Confirms the Stability and Potency of a Novel Formulation of Liquid Levothyroxine
Details : The study examined the potency and consistency of Tirosint-SOL marketed by IBSA Pharma Inc, using the same methodology as the previous study to determine the degree to which the product maintains its labeled potency over a five-week period.
Product Name : Tirosint-SOL
Product Type : Hormone
Upfront Cash : Inapplicable
April 30, 2021
Lead Product(s) : Levothyroxine Sodium
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
